Katherine Longardner
Neurology with Special Qualifications in Child Neurology · San Diego, CANPI 1801215926
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (33.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Lundbeck LLC at 30.2% of the total.
Across 92 payments — averaging $115.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$3K
- Boston Scientific$3K
- Medtronic$2K
- AbbVie$887
- Teva Pharmaceuticals USA, Inc.$616
- Amneal Pharmaceuticals LLC$265
- plus $793 from 10 others
Across 76 payments — averaging $2251.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$171K
What the payments were for
- Consulting fees$1,47514%
- Speaking & faculty fees$3,25431%
- Travel & lodging$3,50833%
- Food & beverage$2,34522%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 1 | $3,200 |
| Boston Scientific | 20 | $2,753 |
| Medtronic(2 entities) | 21 | $2,076 |
| AbbVie(2 entities) | 6 | $887 |
| Teva Pharmaceuticals USA, Inc. | 3 | $616 |
| Amneal Pharmaceuticals LLC | 5 | $265 |
| Merz North America, Inc. | 3 | $233 |
| Abbott | 3 | $165 |
| Adamas Pharmaceuticals, Inc. | 4 | $93 |
| Acadia Pharmaceuticals Inc | 5 | $90 |
| GE HealthCare | 2 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $47 |
| Acorda Therapeutics, Inc | 2 | $47 |
| Lilly USA, LLC | 1 | $21 |
| CSL Behring | 1 | $14 |
| Travere Therapeutics, Inc. | 11 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$1,453
- ACTIVA$1,260
- XEOMIN$225
- PERCEPT PC BRAINSENSE$137
- INFINITY$106
How this compares
$10,590 in reported general payments places this provider in the 80th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 13 | $163,587 |
| RytaryCarbidopa/Levodopa | 83 | $150,949 |
| AustedoDeutetrabenazine | 11 | $145,737 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 201 | $10,350 |
| MyrbetriqMirabegron | 16 | $9,818 |
| Rasagiline Mesylate | 18 | $6,818 |
| Rivastigmine | 12 | $4,704 |
| Midodrine Hcl | 24 | $2,470 |
| AmantadineAmantadine Hcl | 24 | $1,850 |
| RivastigmineRivastigmine Tartrate | 20 | $1,348 |
| Propranolol Hcl | 38 | $557 |
| Ropinirole Hcl | 15 | $545 |
| Fludrocortisone Acetate | 14 | $438 |
| Gabapentin | 20 | $406 |
| Quetiapine Fumarate | 25 | $373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $90 | $163,58713 claims |
| Amneal Pharmaceuticals LLCRytary | $265 | $150,94983 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $616 | $145,73711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in San Diego
- Brittany PassiakSan Diego$90K
- Joseph GleesonSan Diego$69K
- John CrawfordSan Diego$27K
- Richard HaasSan Diego$27K
- Shifteh SattarSan Diego$21K
- Jennifer YangSan Diego$15K
- Doris TraunerSan Diego$15K
- Olivia Kim McManusSan Diego$11K
- Aliya FrederickSan Diego$7K
- Michael ChezSacramento$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.